A549 cells (KRAS-G12D mutation, P53 wide-type), NCI-H2228 (EML4-ALK variant 3, P53 Q331* mutation) and HCC-827 (EGFR exon19 deletion mutant, inactivation P53 mutation) used in the current study contain rearrangements of chromosomes and substantial changes in the genomic landscape. Here, KRAS is linked to hepatocellular carcinoma.